Literature DB >> 29393404

Qiyusanlong decoction suppresses lung cancer in mice via Wnt/β-catenin pathway.

Jia-Bing Tong1, Xing-Xing Zhang1, Xin-Heng Wang2, Shi-Jie Zeng2, Dan-Yang Wang2, Zhi-Qiang Zhang2, Jian Hu2, Chen Yang1, Ze-Geng Li2.   

Abstract

Lung cancer is one of the most fatal cancers due to its high metastatic rate. Traditional Chinese medicine has been used in cancer patients for decades to improve quality of life and prolong survival time. The present study used a novel Qiyusanlong (QYSL) decoction composed of 10 kinds of Chinese medicine including astragalus membranaceus (Huangqi), polygonatumod oratum (yuzu), scolopendra (tianlong), pberetima (dilong), solanum nigrum (longkui), herbahedyotis (baihushecao), semen coicis (yiyiren), euphorbia helioscopia (zeqi), curcuma longa (eshu) and tendril-leaved fritillary bulb (chuanbei). The effects and function of the QYSL decoction remain to be elucidated. The present study established a mouse xenograft model using Lewis lung carcinoma cell injection and administered different doses of QYSL decoction to the mice. It was demonstrated that the chemotherapy drug Cisplatin (DDP) and QYSL decoction repressed lung tumor growth, and the inhibitory effect of DDP was more significant. Furthermore, QYSL decoction and DDP modulated the expression of regulatory proteins in the Wnt/β‑catenin pathway, including Wnt1, Wnt2, Wnt5a and glycogen synthase kinase 3β, detected by western blotting, and affected the signals of cluster of differentiation 44 variation 6 and Survivin in tumor tissues, examined via immunohistochemistry. The combination of QYSL decoction and DDP enhanced the inhibitory effect. These data demonstrated that the QYSL decoction repressed lung tumor development via the Wnt/β‑catenin pathway. The therapeutic effect of QYSL decoction alone was milder compared with DDP, however the combination of QYSL decoction and chemotherapy exhibited an increased the rapeutic effect compared with the treatments administered alone. These findings revealed the function of QYSL decoction as a lung cancer treatment and provided insight for a novel lung cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29393404     DOI: 10.3892/mmr.2018.8478

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

Review 1.  Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer.

Authors:  Yagmur Azbazdar; Mustafa Karabicici; Esra Erdal; Gunes Ozhan
Journal:  Front Cell Dev Biol       Date:  2021-01-21

2.  A plant-based medicinal food inhibits the growth of human gastric carcinoma by reversing epithelial-mesenchymal transition via the canonical Wnt/β-catenin signaling pathway.

Authors:  Xuxi Chen; Wuyang Yue; Lin Tian; Na Li; Yiyi Chen; Lishi Zhang; Jinyao Chen
Journal:  BMC Complement Med Ther       Date:  2021-05-08

3.  An Integrated Strategy of Chemical Fingerprint and Network Pharmacology for the Discovery of Efficacy-Related Q-Markers of Pheretima.

Authors:  Ye Shang; Suyi Liu; Chunxiao Liang; Kunze Du; Shujing Chen; Jin Li; Hua Jin; Yanxu Chang
Journal:  Int J Anal Chem       Date:  2022-10-04       Impact factor: 1.698

4.  Qiyusanlong Formula Induces Autophagy in Non-Small-Cell Lung Cancer Cells and Xenografts through the mTOR Signaling Pathway.

Authors:  Yating Gao; Xinheng Wang; Qinjun Yang; Xiaole Wang; Xingxing Zhang; Jiabing Tong; Cheng Yang; Di Wu; Zegeng Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-22       Impact factor: 2.629

5.  YYFZBJS ameliorates colorectal cancer progression in ApcMin/+ mice by remodeling gut microbiota and inhibiting regulatory T-cell generation.

Authors:  Hua Sui; Lu Zhang; Kaijuan Gu; Ni Chai; Qing Ji; Lihong Zhou; Yan Wang; Junze Ren; Limei Yang; Bimeng Zhang; Jing Hu; Qi Li
Journal:  Cell Commun Signal       Date:  2020-07-16       Impact factor: 5.712

6.  Ligustrazine eases lung cancer by regulating PTEN and Wnt/β-catenin pathway.

Authors:  Yuehua Dong; Yanjun Yang; Yulei Wei; Yongshan Gao; Weihua Jiang; Guigang Wang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.